Laurence E. Krieger

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma

Carole A. Harris, Danka Sinikovic Zebic, M. Morrison, Tom Ferguson et autres

au (code pays fourni par la source)

Saruparib + androgen receptor pathway inhibitor (ARPI) + androgen deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase 1/2 PETRANHA trial.

Arun Azad, Patrick G. Pilié, Mark Voskoboynik, Frank C. Cackowski et autres

au, us, it, gb, nl, sg (code pays fourni par la source)

Outcomes in participants (pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC) who underwent radical cystectomy (RC) after pembrolizumab (pembro): KEYNOTE-057 cohort A post hoc analysis.

Edward M. Uchio, G. Kulkarni, Joost L. Boormans, M. Roumiguie et autres

us, ca, nl, fr, au, kr, jp (code pays fourni par la source)

WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide

Barak Talmor, Carole A. Harris, Christopher Gianacas, David Pook et autres

au, us (code pays fourni par la source)

Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin–naïve Non–muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)

Dickon Hayne, Alison Y. Zhang, Hayley Thomas, Laurence E. Krieger et autres

au, us (code pays fourni par la source)

3205eP Analysis of X posts during ESMO 2024 by Medical Watch

S. Chowdhury, Simon Hughes, A.J. Birtle, A.S. Merseburger et autres

us, gb, de, tr, sg, au (code pays fourni par la source)

2384MO First interim efficacy analysis of the phase I/II PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC)

Arun Azad, Anthony M. Joshua, Mark Voskoboynik, Peter Sankey et autres

au, gb, us, it, nl, sg (code pays fourni par la source)

Mitomycin plus BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: A randomized phase 3 trial (ANZUP 1301).

Dickon Hayne, Alison Yan Zhang, Hayley Thomas, Cynthia Hawks et autres

au, gb (code pays fourni par la source)

First-in-human study of RAG-01: A novel small activating RNA therapeutic in BCG failure non-muscle invasive bladder cancer (NMIBC) patients.

Laurence E. Krieger

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Anthony M. Joshua et autres

au (code pays fourni par la source)

Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).

Megan Crumbaker, Laurence E. Krieger, David Pook, Ian D. Davis et autres

au, us (code pays fourni par la source)

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

Fred Saad, Egils Vjaters, Neal D. Shore, David Olmos et autres

ca, lv, us, es, cn, lt, ru, fi, it, fr, de, in (code pays fourni par la source)